C4 Therapeutics, Inc. Operating Cash Flow
C4 Therapeutics, Inc. (CCCC) reported Operating Cash Flow of -$31.52 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-11
- C4 Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$1.57M.
- C4 Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$29.94M.
- C4 Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$22.14M.
- C4 Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$31.21M.
- C4 Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$98.69M.
- C4 Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$65.16M.
- C4 Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$106.84M.
- C4 Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$105.94M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$1.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$31.52M 10-Q · filed 2026-08-11 | -$53.66M derived: sum of 3 quarters · filed 2026-08-11 | -$84.87M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | -$29.94M 10-Q · filed 2026-05-12 | -$52.09M derived: sum of 2 quarters · filed 2026-05-12 | -$83.30M derived: sum of 3 quarters · filed 2026-05-12 | -$95.35M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-12-31 | -$22.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$53.35M derived: sum of 2 quarters · filed 2026-02-26 | -$65.41M derived: sum of 3 quarters · filed 2026-08-11 | -$98.69M 10-K · filed 2026-02-26 | |
| 2025-09-30 | -$31.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$43.26M derived: sum of 2 quarters · filed 2026-08-11 | -$76.55M 10-Q · filed 2025-11-06 | -$94.48M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-06-30 | -$12.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$45.34M 10-Q · filed 2026-08-11 | -$63.27M derived: sum of 3 quarters · filed 2026-08-11 | -$87.41M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-03-31 | -$33.28M 10-Q · filed 2026-05-12 | -$51.22M derived: sum of 2 quarters · filed 2026-05-12 | -$75.35M derived: sum of 3 quarters · filed 2026-05-12 | -$80.32M derived: sum of 4 quarters · filed 2026-05-12 | |
| 2024-12-31 | -$17.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$42.06M derived: sum of 2 quarters · filed 2026-02-26 | -$47.04M derived: sum of 3 quarters · filed 2026-02-26 | -$65.16M 10-K · filed 2026-02-26 | |
| 2024-09-30 | -$24.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$29.11M derived: sum of 2 quarters · filed 2025-11-06 | -$47.23M 10-Q · filed 2025-11-06 | -$71.23M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | -$4.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$23.09M 10-Q · filed 2025-08-07 | -$47.10M derived: sum of 3 quarters · filed 2025-08-07 | -$77.81M derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | -$18.12M 10-Q · filed 2025-05-07 | -$42.13M derived: sum of 2 quarters · filed 2025-05-07 | -$72.83M derived: sum of 3 quarters · filed 2025-05-07 | -$91.83M derived: sum of 4 quarters · filed 2025-05-07 | |
| 2023-12-31 | -$24.01M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$54.72M derived: sum of 2 quarters · filed 2025-02-27 | -$73.71M derived: sum of 3 quarters · filed 2025-02-27 | -$106.84M 10-K · filed 2025-02-27 | |
| 2023-09-30 | -$30.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | -$49.70M derived: sum of 2 quarters · filed 2024-10-31 | -$82.83M 10-Q · filed 2024-10-31 | -$111.96M derived: sum of 4 quarters · filed 2024-10-31 | |
| 2023-06-30 | -$19.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$52.12M 10-Q · filed 2024-08-01 | -$81.25M derived: sum of 3 quarters · filed 2024-08-01 | -$109.27M derived: sum of 4 quarters · filed 2024-08-01 | |
| 2023-03-31 | -$33.13M 10-Q · filed 2024-05-08 | -$62.25M derived: sum of 2 quarters · filed 2024-05-08 | -$90.27M derived: sum of 3 quarters · filed 2024-05-08 | -$112.47M derived: sum of 4 quarters · filed 2024-05-08 | |
| 2022-12-31 | -$29.13M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$57.15M derived: sum of 2 quarters · filed 2024-02-22 | -$79.34M derived: sum of 3 quarters · filed 2024-02-22 | -$105.94M 10-K · filed 2024-02-22 | |
| 2022-09-30 | -$28.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | -$50.22M derived: sum of 2 quarters · filed 2023-11-01 | -$76.81M 10-Q · filed 2023-11-01 | -$102.48M derived: sum of 4 quarters · filed 2023-11-01 | |
| 2022-06-30 | -$22.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$48.79M 10-Q · filed 2023-08-08 | -$74.46M derived: sum of 3 quarters · filed 2023-08-08 | -$92.82M derived: sum of 4 quarters · filed 2023-08-08 | |
| 2022-03-31 | -$26.60M 10-Q · filed 2023-05-04 | -$52.27M derived: sum of 2 quarters · filed 2023-05-04 | -$70.63M derived: sum of 3 quarters · filed 2023-05-04 | -$88.63M derived: sum of 4 quarters · filed 2023-05-04 | |
| 2021-12-31 | -$25.67M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$44.03M derived: sum of 2 quarters · filed 2023-02-23 | -$62.03M derived: sum of 3 quarters · filed 2023-02-23 | -$86.97M 10-K · filed 2023-02-23 | |
| 2021-09-30 | -$18.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$36.36M derived: sum of 2 quarters · filed 2022-11-03 | -$61.29M 10-Q · filed 2022-11-03 | -$82.89M derived: sum of 4 quarters · filed 2022-11-03 | |
| 2021-06-30 | -$18.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$42.94M 10-Q · filed 2022-08-04 | -$64.53M derived: sum of 3 quarters · filed 2022-08-04 | -$78.92M derived: sum of 4 quarters · filed 2022-08-04 | |
| 2021-03-31 | -$24.93M 10-Q · filed 2022-05-05 | -$46.53M derived: sum of 2 quarters · filed 2022-05-05 | -$60.92M derived: sum of 3 quarters · filed 2022-05-05 | -$75.52M derived: sum of 4 quarters · filed 2022-05-05 | |
| 2020-12-31 | -$21.59M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$35.99M derived: sum of 2 quarters · filed 2022-02-24 | -$50.58M derived: sum of 3 quarters · filed 2022-02-24 | -$67.25M 10-K · filed 2022-02-24 | |
| 2020-09-30 | -$14.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$28.99M derived: sum of 2 quarters · filed 2021-11-10 | -$45.66M 10-Q · filed 2021-11-10 | -$45.71M 10-Q · filed 2020-11-12 | -$55.96M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | -$14.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | -$31.26M 10-Q · filed 2021-08-11 | -$41.56M derived: sum of 3 quarters · filed 2022-02-24 | ||
| 2020-03-31 | -$16.67M 10-Q · filed 2021-05-13 | -$26.97M derived: sum of 2 quarters · filed 2022-02-24 | |||
| 2019-12-31 | -$10.30M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $55.61M 10-K · filed 2022-02-24 | |||
| 2019-09-30 | $65.92M 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |